MALLINCKRODT ALBUNEX TEST MARKETING TO BEGIN IN EARLY SEPTEMBER
This article was originally published in The Gray Sheet
Executive SummaryMALLINCKRODT ALBUNEX TEST MARKETING TO BEGIN IN EARLY SEPTEMBER at 10 hospitals following FDA clearance of the product Aug. 5. The approval is the agency's first for an ultrasound contrast imaging agent for use in the left side of the heart. Albunex was developed by Molecular Biosystems, Inc.; Mallinckrodt Medical has marketing rights in North and South America.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.